FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

1251599007: Myeloid neoplasm post cytotoxic therapy (morphologic abnormality)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Mar 2023. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
5134344014 Myeloid neoplasm post cytotoxic therapy (morphologic abnormality) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
5134345010 Myeloid neoplasm post cytotoxic therapy en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Myeloid neoplasm post cytotoxic therapy (morphologic abnormality) Is a Malignant hematopoietic neoplasm (morphologic abnormality) true Inferred relationship Some
Myeloid neoplasm post cytotoxic therapy (morphologic abnormality) Is a Myeloid neoplasm (morphologic abnormality) true Inferred relationship Some
Inbound Relationships Type Active Source Characteristic Refinability Group
Therapy-related myelodysplastic syndrome (disorder) Associated morphology True Myeloid neoplasm post cytotoxic therapy (morphologic abnormality) Inferred relationship Some 1
A subgroup of therapy-related myeloid neoplasms (t-MN), associated with a treatment of an unrelated neoplastic or autoimmune disease with cytotoxic agents, like cyclophosphamid, platins, melphalan and others. The neoplastic cells typically harbour unbalanced aberrations of chromosomes 5 and 7 (monosomy 5/del(5q) and monosomy 7/del(7q)) or a complex karyotype. It usually presents with multilineage dysplasia and cytopenias 5-10 years after exposure, with symptoms related to the degree of bone marrow failure and the corresponding cytopenia (fatigue, bleeding and bruising, recurrent infections, bone pain). Associated morphology True Myeloid neoplasm post cytotoxic therapy (morphologic abnormality) Inferred relationship Some 1
A subgroup of therapy-related myeloid neoplasms (t-MN), associated with treatment of an unrelated neoplastic disease with cytotoxic agents, like etoposide, doxorubicin, daunorubicin and others. The neoplastic cells often show rearrangements involving the mixed lineage leukaemia gene at 11q23. This subgroup of t-MN is typically associated with overt leukaemia, without preceding myelodysplastic syndrome, developing 2-3 years after exposure, presenting with non-specific symptoms related to ineffective haematopoesis (fatigue, bleeding and bruising, recurrent infections, bone pain) and/or extramedullary site involvement. Associated morphology True Myeloid neoplasm post cytotoxic therapy (morphologic abnormality) Inferred relationship Some 1
A subgroup of therapy-related myeloid neoplasms (t-MN), associated with treatment of an unrelated neoplastic disease with radiation. The neoplastic cells typically harbor unbalanced aberrations of chromosomes 5 and 7 (monosomy 5/del(5q) and monosomy 7/del(7q)) or a complex karyotype. Patients frequently present with multilineage dysplasia and cytopenias 5-10 years after exposure. Associated morphology True Myeloid neoplasm post cytotoxic therapy (morphologic abnormality) Inferred relationship Some 1
Therapy related acute myeloid leukemia and myelodysplastic syndrome (disorder) Associated morphology True Myeloid neoplasm post cytotoxic therapy (morphologic abnormality) Inferred relationship Some 1
Therapy related acute myeloid leukaemia due to and following administration of antineoplastic agent Associated morphology True Myeloid neoplasm post cytotoxic therapy (morphologic abnormality) Inferred relationship Some 3

This concept is not in any reference sets

Back to Start